Europe (WHO region) vs Oman: Previously treated cases tested for RR-/MDR-TB
Europe (WHO region)
90.0%
in 2024
Oman
100.0%
in 2024
Europe (WHO region) rank
2nd
Oman rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Europe (WHO region)
- Oman
How they compare
Oman currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Oman's figure about 1.1 times Europe (WHO region)'s.
Across all 19 years both countries report, Oman has been ahead every year.
Europe (WHO region) ranks 2nd and Oman ranks 1st of 11 groups.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 20.2% | 100.0% | 79.8% | Oman |
| 2010s | 57.7% | 96.9% | 39.2% | Oman |
| 2020s | 93.5% | 100.0% | 6.5% | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Europe (WHO region) or Oman?
- Oman, at 100.0% against 90.0% in Europe (WHO region) as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Europe (WHO region) and Oman?
- 10.0%, with Oman ahead.
- How many years of comparable data are there for Europe (WHO region) and Oman?
- 19 years are reported by both, from 2005 to 2024.
- How do Europe (WHO region) and Oman rank globally for previously treated cases tested for rr-/mdr-tb?
- Europe (WHO region) ranks 2nd and Oman ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.